The sNDA for empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure and slow kidney function decline in adults with chronic heart failure with ...

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

Results for EMPEROR-Reduced have been highly anticipated, as they are expected to set off a new round of competition in the drug class, which was first developed to treat type 2 diabetes.

Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...

The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

SAN FRANCISCO, March 3, 2025 /PRNewswire/ -- Eko Health, a leader in artificial intelligence (AI) for the early detection of heart and lung diseases, today announced the publication of a peer-reviewed ...

ST. PAUL, Minn. & SAN DIEGO, Calif. -- St. Jude Medical, Inc., a global medical device company, today announced a new data analysis from the CHAMPION trial showing that heart failure (HF) patients ...

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...